Share on StockTwits

Argos Therapeutics’ (NASDAQ:ARGS) lock-up period will end on Wednesday, August 6th. Argos Therapeutics had issued 5,625,000 shares in its IPO on February 7th, AnalystRatingsNetwork.com reports. The total size of the offering was $45,000,000 based on an initial share price of $8.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Argos Therapeutics (NASDAQ:ARGS) traded up 0.67% during mid-day trading on Friday, hitting $6.02. The stock had a trading volume of 48,222 shares. Argos Therapeutics has a 52 week low of $5.611 and a 52 week high of $13.74. The stock has a 50-day moving average of $6.89 and a 200-day moving average of $8.53. The company’s market cap is $118.3 million.

Argos Therapeutics (NASDAQ:ARGS) last released its earnings data on Tuesday, May 13th. The company reported ($1.05) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.46) by $0.59. The company had revenue of $0.80 million for the quarter, compared to the consensus estimate of $1.26 million. Analysts expect that Argos Therapeutics will post $-2.72 EPS for the current fiscal year.

Argos Therapeutics Inc is a United States-based biopharmaceutical company. The company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis technology platform.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.